Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for …
KM Chow, WZ So, HJ Lee, A Lee, DWT Yap… - European urology, 2023 - Elsevier
Context Whether prostate-specific membrane antigen positron emission tomography (PSMA-
PET) should replace conventional imaging modalities (CIM) for initial staging of intermediate …
PET) should replace conventional imaging modalities (CIM) for initial staging of intermediate …
Can negative prostate-specific membrane antigen positron emission tomography/computed tomography avoid the need for pelvic lymph node dissection in newly …
Context The role of positron emission tomography/computed tomography (PET/CT) with
prostate-specific membrane antigen (PSMA) in the primary staging for patients with prostate …
prostate-specific membrane antigen (PSMA) in the primary staging for patients with prostate …
Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter …
TA Hope, M Eiber, WR Armstrong, R Juarez… - JAMA …, 2021 - jamanetwork.com
Importance The presence of pelvic nodal metastases at radical prostatectomy is associated
with biochemical recurrence after prostatectomy. Objective To assess the accuracy of …
with biochemical recurrence after prostatectomy. Objective To assess the accuracy of …
[HTML][HTML] Diagnostic performance and safety of positron emission tomography with 18F-rhPSMA-7.3 in patients with newly diagnosed unfavourable intermediate-to very …
DS Surasi, M Eiber, T Maurer, MA Preston, BT Helfand… - European urology, 2023 - Elsevier
Abstract Background Radiohybrid (rh) 18 F-rhPSMA-7.3 is a novel high-affinity prostate-
specific membrane antigen (PSMA)-targeting radiopharmaceutical for prostate cancer (PCa) …
specific membrane antigen (PSMA)-targeting radiopharmaceutical for prostate cancer (PCa) …
Using PSMA imaging for prognostication in localized and advanced prostate cancer
MJ Roberts, T Maurer, M Perera, M Eiber… - Nature Reviews …, 2023 - nature.com
The use of prostate-specific membrane antigen (PSMA)-directed applications in modern
prostate cancer management has evolved rapidly over the past few years, helping to …
prostate cancer management has evolved rapidly over the past few years, helping to …
Incorporating prostate-specific membrane antigen positron emission tomography in management decisions for men with newly diagnosed or biochemically recurrent …
Context Prostate-specific membrane antigen (PSMA) is a promising molecular target for
prostate cancer (PCa) that has allowed the development of a novel diagnostic approach to …
prostate cancer (PCa) that has allowed the development of a novel diagnostic approach to …
[HTML][HTML] Targeting PSMA revolutionizes the role of nuclear medicine in diagnosis and treatment of prostate cancer
Simple Summary Imaging plays a crucial role in the accurate staging of prostate cancer.
Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer cells, and …
Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer cells, and …
[HTML][HTML] Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate …
Purpose To prospectively compare 18 F-prostate-specific membrane antigen (PSMA)-1007
positron emission tomography (PET)/CT, whole-body magnetic resonance imaging (WBMRI) …
positron emission tomography (PET)/CT, whole-body magnetic resonance imaging (WBMRI) …
Piflufolastat F 18: diagnostic first approval
SJ Keam - Molecular Diagnosis & Therapy, 2021 - Springer
Abstract Piflufolastat F 18 (PYLARIFY®) is an 18 F-labelled diagnostic imaging agent that
has been developed by Progenics Pharmaceuticals Inc., a Lantheus company, for positron …
has been developed by Progenics Pharmaceuticals Inc., a Lantheus company, for positron …
[HTML][HTML] The role of PSMA PET/CT in the primary diagnosis and follow-up of prostate cancer—a practical clinical review
AR Lisney, C Leitsmann, A Strauß, B Meller… - Cancers, 2022 - mdpi.com
Simple Summary The combination of positron emission tomography (PET)-diagnostics with
ligands binding to the prostate-specific membrane antigen (PSMA) has been a diagnostic …
ligands binding to the prostate-specific membrane antigen (PSMA) has been a diagnostic …